SUPPLEMENTAL MATERIAL

Table S1. Interaction between internet participation and randomized dose with respect to outcomes (adherence and clinical).

	CIF* Estimate at Median Follow-up (26.2 months)		Incidence Rate (Events per 100 Patient Years of Follow-up)		Unadjusted		Adjusted‡	
Outcome	**81 mg**	**325 mg**	**81 mg**	**325 mg**	**Hazard Ratio (95% CI)**	**P-value**	**Hazard Ratio (95% CI)**	**P-value**
Medication Adherence Endpoint: dose switching or aspirin discontinuation						0.014		0.019
Internet Participant	18.58%	55.42%	10.79 (1053)	41.89 (3118)	0.28 (0.26 - 0.30)		0.28 (0.26 - 0.30)	
Non-internet Participant	24.96%	73.08%	14.33 (193)	77.89 (595)	0.23 (0.19 - 0.27)		0.23 (0.19 - 0.27)	
Composite Clinical Endpoint: all-cause death, myocardial infarction, or stroke						0.150		0.108
Internet Participant	6.28%	6.70%	3.09 (439)	3.19 (449)	0.97 (0.85 - 1.10)		0.97 (0.85 - 1.11)	
Non-internet Participant	13.73%	12.96%	7.29 (151)	6.16 (120)	1.18 (0.93 - 1.50)		1.22 (0.96 - 1.55)	
Safety Endpoint: Major bleeding with associated blood product transfusion						0.477		0.440
Internet Participant	0.60%	0.57%	0.28 (41)	0.26 (37)	1.10** (0.70 - 1.71)		1.11 (0.71 - 1.75)	
Non-internet Participant	0.80%	0.76%	0.56 (12)	0.35 (7)	1.60† (0.63 - 4.05)		1.67 (0.66 - 4.23)	

*CIF: Cumulative Incidence Function
†Sub-distribution hazard ratio (SHR)
‡Models adjusted for age, sex, race, ethnicity and invitation method.

Table S2. Baseline characteristics and trial details of participants by internet participation at randomization and last observed visit.

		Internet Participation at Randomization		Non-Internet Participation at Randomization	
Characteristic	**Overall (N=15,076)**	**Internet** Participant- **Last Visit (N=11,474)**	**Non-internet** Participant- **Last Visit (N=1,698)**	**Internet** Participant- **Last Visit (N=13)**	**Non-internet** Participant- **Last Visit (N=1,891)**
Age (yrs): median (IQR)	68 (61 - 74)	67 (60 - 73)	68 (61 - 74)	62 (56 - 67)	69 (63 - 76)
Female	4724 (31.3%)	3428 (29.9%)	556 (32.7%)	5 (38.5%)	735 (38.9%)
Race					
White	11990 (79.5%)	9695 (84.5%)	1250 (73.6%)	9 (69.2%)	1036 (54.8%)
Black or African American	1311 (8.7%)	600 (5.2%)	191 (11.2%)	3 (23.1%)	517 (27.3%)
Asian	146 (1.0%)	107 (0.9%)	13 (0.8%)	0 (0.0%)	26 (1.4%)
American Indian or Alaska native	114 (0.8%)	74 (0.6%)	14 (0.8%)	0 (0.0%)	26 (1.4%)
Multiple	134 (0.9%)	101 (0.9%)	15 (0.9%)	1 (7.7%)	17 (0.9%)
Other	401 (2.7%)	168 (1.5%)	34 (2.0%)	0 (0.0%)	199 (10.5%)
Not reported	980 (6.5%)	729 (6.4%)	181 (10.7%)	0 (0.0%)	70 (3.7%)
Hispanic	481 (3.2%)	224 (2.0%)	45 (2.7%)	0 (0.0%)	212 (11.2%)
Smoking Status					
Current	1382 (9.8%)	870 (8.2%)	223 (13.4%)	3 (23.1%)	286 (15.2%)
Body Mass Index: median (IQR)	30 (27 - 34)	30 (27 - 34)	30 (27 - 35)	32 (29 - 36)	30 (26 - 34)
Trial Details					
Randomized Dose					
81 mg	7540 (50.0%)	5720 (49.9%)	840 (49.5%)	5 (38.5%)	975 (51.6%)

325 mg	7536 (50.0%)	5754 (50.1%)	858 (50.5%)	8 (61.5%)	916 (48.4%)
Randomized Follow-up Interval					
3 Months	7541 (50.0%)	5775 (50.3%)	829 (48.8%)	7 (53.8%)	930 (49.2%)
6 Months	7535 (50.0%)	5699 (49.7%)	869 (51.2%)	6 (46.2%)	961 (50.8%)
Invitation Method					
Received an Email	5900 (39.1%)	5344 (46.6%)	503 (29.6%)	2 (15.4%)	51 (2.7%)
Received a Letter	3400 (22.6%)	2741 (23.9%)	352 (20.7%)	1 (7.7%)	306 (16.2%)
Approached face-to-face in a clinical setting	4080 (27.1%)	2113 (18.4%)	574 (33.8%)	9 (69.2%)	1384 (73.2%)
Contacted by Telephone	1695 (11.2%)	1275 (11.1%)	269 (15.8%)	1 (7.7%)	150 (7.9%)
Medical History					
Prior Myocardial Infarction	5305 (36.2%)	3768 (33.9%)	648 (39.0%)	8 (61.5%)	881 (46.7%)
Prior CABG*	3527 (24.1%)	2548 (23.0%)	432 (26.0%)	2 (15.4%)	545 (28.9%)
Prior PCI†	5946 (40.6%)	4257 (38.3%)	733 (44.2%)	7 (53.8%)	949 (50.3%)
Cerebrovascular Disease	2624 (17.9%)	1829 (16.5%)	321 (19.3%)	4 (30.8%)	470 (24.9%)
Hypertension	12512 (85.3%)	9303 (83.8%)	1448 (87.2%)	12 (92.3%)	1749 (92.7%)
Hyperlipidemia	12946 (88.3%)	9748 (87.8%)	1493 (89.9%)	11 (84.6%)	1694 (89.8%)
Atrial Fibrillation	1233 (8.4%)	924 (8.3%)	147 (8.9%)	0 (0.0%)	162 (8.6%)
Congestive Heart Failure	3504 (23.9%)	2345 (21.1%)	460 (27.7%)	4 (30.8%)	695 (36.8%)
Peripheral Artery Disease	3493 (23.8%)	2321 (20.9%)	444 (26.7%)	1 (7.7%)	727 (38.5%)
Diabetes Mellitus	5676 (38.7%)	3977 (35.8%)	720 (43.4%)	5 (38.5%)	974 (51.6%)
History of Bleeding	1267 (8.6%)	862 (7.8%)	170 (10.2%)	2 (15.4%)	233 (12.3%)
Significant Gastrointestinal Bleed	950 (6.5%)	640 (5.8%)	123 (7.4%)	2 (15.4%)	185 (9.8%)
Intracranial Hemorrhage	208 (1.4%)	142 (1.3%)	28 (1.7%)	0 (0.0%)	38 (2.0%)
Prior Medications					

Prior Aspirin Use	13537 (96.0%)	10098 (95.7%)	1578 (95.1%)	11 (84.6%)	1850 (98.6%)
Prior Dose					
81 mg	11547 (85.4%)	8580 (85.1%)	1343 (85.5%)	11 (100.0%)	1613 (87.3%)
162 mg	310 (2.3%)	256 (2.5%)	28 (1.8%)	0 (0.0%)	26 (1.4%)
325 mg	1657 (12.3%)	1249 (12.4%)	200 (12.7%)	0 (0.0%)	208 (11.3%)
P2Y12 Inhibitor	3051 (22.1%)	2187 (21.0%)	386 (25.2%)	1 (8.3%)	477 (25.5%)
Trial Adherence					
Percentage of Visits Completed: median (IQR)	88 (67 - 100)	93 (67 - 100)	75 (60 - 86)	89 (83 - 100)	89 (73 - 100)
Categories of Visit Completion					
0%	775 (5.1%)	763 (6.7%)	2 (0.1%)	0 (0.0%)	10 (0.5%)
1-25%	659 (4.4%)	506 (4.4%)	39 (2.3%)	1 (7.7%)	113 (6.0%)
26-50%	1428 (9.5%)	1011 (8.8%)	241 (14.2%)	0 (0.0%)	176 (9.3%)
51-75%	2589 (17.2%)	1646 (14.3%)	659 (38.8%)	0 (0.0%)	284 (15.0%)
76-99%	2779 (18.4%)	1838 (16.0%)	412 (24.3%)	7 (53.8%)	522 (27.6%)
100%	6842 (45.4%)	5707 (49.8%)	345 (20.3%)	5 (38.5%)	785 (41.5%)
Number of Visits Completed with Call Center Assistance	2 (1 - 3)	1 (1 - 2)	3 (2 - 4)	3 (2 - 3)	4 (2 - 6)

*CABG: coronary artery bypass graft

†PCI: percutaneous intervention

Figure S1. Safety Endpoint: Major Bleeding Requiring Hospitalization.



Cumulative incidence function (CIF) curve for major bleeding by internet participation at randomization. At the median time of follow-up in the study, non-internet participants had more major bleeding events, widening the gap until the end of the study.